Updated:
SK bioscience
SK bioscience is a South Korea-based biopharmaceutical company focused on vaccines and biologics.
SK bioscience
SK bioscience is a South Korea-based biopharmaceutical company focused on vaccines and biologics. The firm was spun out from SK Group, though its founding year is not publicly specified. Its headquarters are in Seongnam, while a global R&D center in Songdo achieved LEED Gold certification in 2026. The company operates across three business pillars: development of own vaccines, import and distribution of partnered products, and CDMO/CMO services. It has collaborations with global partners such as the University of Washington and Sanofi, and its pipeline covers HPV, shingles, and pneumococcal vaccines. Geographically, it serves markets in Asia, Latin America, and Europe through subsidiaries SK bioscience USA and IDT Biologika. As of May 2026, SK bioscience announced a funding agreement with the National Growth Fund, as disclosed by the board. The firm reported Q1 2026 results that showed growth in revenue alongside increased investment in future R&D. Its Songdo R&D center was also certified LEED Gold, reflecting sustainability commitments. SK bioscience's structural differentiator lies in its hybrid model: it competes as both a vaccine innovator and a manufacturing partner, leveraging its own pipeline alongside CDMO capacity. The company also tied employee compensation to stock via a 17.1 billion won share buyback for RSU grants in April 2026. Its governance remains under SK Group, making it a corporate-backed entity rather than a traditional family office or standalone asset manager.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Seongnam
Corporate office
Seongnam, South Korea
Additional offices
R&D center in Songdo, South Korea; SK bioscience USA; IDT Biologika
Principals
CEO (name not disclosed on public website)
CEO
Sector focus
Frequently asked questions
Who runs investment decisions at SK bioscience?
SK bioscience discloses its CEO on its website but does not publicly name the individual. The CEO oversees the company's strategic and investment decisions. Board governance follows SK Group structure.
How does SK bioscience source proprietary deal flow?
SK bioscience develops its own vaccines and biologics pipeline, including programs for HPV, shingles, and pneumococcal disease. It also enters into technology transfer and co-development agreements, as seen with the Colombia deal in May 2026.
Is SK bioscience structured as a family office or a corporate entity?
SK bioscience operates as a publicly traded corporation on the KOSPI under ticker 302440. It is a subsidiary of SK Group, a South Korean conglomerate. It is not a family office.
What investment stages does SK bioscience typically target?
SK bioscience focuses on late-stage development, manufacturing, and commercialization of vaccines and biologics. It also engages in early-stage research through its global R&D center. Its CDMO/CMO business serves both own and external pipelines.
Which sectors does SK bioscience explicitly avoid?
SK bioscience does not specify sectors it avoids, but its activities concentrate on vaccines and biologics. It does not operate in small-molecule drugs or medical devices based on public disclosures.
How is SK bioscience related to SK Group?
SK bioscience is a publicly traded subsidiary of SK Group, a major South Korean conglomerate. SK Group is involved in energy, telecommunications, and semiconductors among other sectors. SK bioscience's shares are listed on the KOSPI.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: